Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 5NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Herpesviridae Infections 1HIV Infections 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Acquired Immunodeficiency Syndrome 1AIDS-Related Opportunistic Infections 1

Interventions

Cyclophosphamide 178Radiotherapy 147Paclitaxel 128Carboplatin 124Bevacizumab 123Cisplatin 119Doxorubicin 111Fluorouracil 107Etoposide 102Filgrastim 99Vincristine 88Leucovorin 82Bortezomib 80Gemcitabine 76aldesleukin 74Sorafenib 70Cytarabine 70Taxes 69fludarabine phosphate 67Irinotecan 66Docetaxel 64Oxaliplatin 60sargramostim 58Sirolimus 58temsirolimus 56Erlotinib Hydrochloride 56Methotrexate 55Rituximab 54Vorinostat 52Radiation 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NIH × Acyclovir × Clear all
NCT00061945 2022-05-03

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
302 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00000712 2021-11-04

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
400 enrolled

Acquired Immunodeficiency Syndrome, Cytomegalovirus Infections, Herpesviridae Infections, HIV Infections, AIDS-Related Opportunistic Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡